Sydney M Crago

Ying Han, MD, PhD discusses glaucoma management strategies, including transitioning care between ophthalmologists and optometrists, improving diagnosis, and the hope for future glaucoma developments.

PST-611, a first in class non-viral vectorized therapy expressing human transferrin, a highly potent iron regulator.

Shah discusses several studies from the IRIS registry and plans for a retina program at next year's event to address the growing interest in retina procedures and techniques.

The topline results from the COAST trial is anticipated in early Q2 of 2025.

The company plans on launching VIA360 immediately in the US market.

The submission deadline for both the 2025 Jenny Pomeroy Award for Excellence in Vision and Public Health and the sixth annual Rising Visionary Award is Monday, March 10, 2025, at noon ET.

The funding is allocated to support the clinical development of the company's non-incisional refractive correction procedure that leverages corneal cross-linking (CXL) to reshape the cornea.

A recent study of AEYE-DS AI technology used in conjunction with the Topcon NW500 resulted in exceptional clinical diagnostic efficacy.

Yvonne Ou, MD, a professor of ophthalmology at the University of California San Francisco, spoke about lifestyle modifications for glaucoma at this year's Glaucoma 360 meeting.

M. Roy Wilson, presented the Shaffer-Hetherington-Hoskins Lecture at the Glaucoma 360 meeting held in San Francisco, California. This lecture was entitled, "Rethinking Race as a Risk Factor for Glaucoma: What Really Matters?"

Ophthalmology Times spoke with Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis about how her research can align with human glaucoma research to move the entire field

Sunita Radhakrishnan, MD, shares insights on the use of electric neurostimulation and its potential use in the treatment of glaucoma, as evidenced by its current use in Europe and the upcoming trials for use in the US.

Shan Lin, MD, speaks to the new MIGS entering the glaucoma space and providing additional options for patients and providers as they work to preserve vision and work towards a better future for glaucoma treatment options.

Andrew Iwach, MD, co-founder of the Glaucoma 360 meeting shares that value this meeting has for residents and fellows as they embark on their careers and the future additions to the meeting that will include retina discussions.

Inder Paul Singh, MD, speaks to the potential of artificial intelligence (AI) in the management of the glaucoma disease state as well as the current challenges of drug delivery in treating patients with glaucoma.

John Berdahl, MD, discusses a non-surgical, non-drug treatment for glaucoma approved by the FDA in 2024. The pump uses negative pressure to lower eye pressure by an average of 39% in clinical trials, with a good safety profile.

Andrew Iwach, MD, shares how Glaucoma 360 got its start and how today's meeting focuses on innovation that can benefit patients with glaucoma as the condition is monitored and treated.

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration (iAMD) and diabetic retinal eye disease.

Positive efficacy and safety data were observed at 3 months after a single injection of K8 in this study conducted at the University of Kentucky.

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.

This trial is designed to evaluate 4D-150 in diabetic macular edema.

OCU400 demonstrated meaningful improvement of 2-line gain (10 letters on ETDRS chart) in low-luminance visual acuity (LLVA) in treated eyes when compared to untreated fellow eyes.

Several companies have announced new executives and board members appointments as they prepare for growth in 2025.

The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration and Astellas.

Catch up on the clinical trial news, updates from the United States Food and Drug Administration (FDA), and company funding you may have missed.

ArMaDa clinical trial is set to assess the safety and efficacy of unilateral subretinal administration of OCU410 in patients with GA

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

Look back on some of the top stories on Modern Retina from 2024 as we gear up for an incredible 2025.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.